Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine against COVID-19.
Read more here.
Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine against COVID-19.
Read more here.
![[Morphisec in PRWeb] Morphisec Announces 2019 Women in Cybersecurity Scholarship Winners](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
